The global somatostatin analogs treatment market size is
expected to reach USD 8.9 billion by 2026, expanding at a CAGR of 6.3% during
the forecast period, according to a new report by Grand View Research, Inc.
Increasing awareness of diseases such as acromegaly and neuroendocrine tumors
is expected to be the vital impact rendering driver.
Presence of strong pipeline products is one of
the major factors driving the market growth over the forecast period. For
instance, Camurus AB is developing CAM2029 for the treatment of acromegaly and
is currently under phase 3 clinical trial. This product comprises of octreotide
as its main ingredient. The product is also under phase 1/2 trials for the
treatment of neuroendocrine tumors. Furthermore, Dauntless Pharmaceuticals is
developing DP1038, an intranasal octreotide, and is currently under clinical
development.
Existence of different online portals
providing related information on various diseases is anticipated to create
awareness among the population. For instance, Neuroendocrine Cancer Awareness
Network provides all the information related to their symptoms, available
treatment options and disease management.
In addition, this network exhibits at the
medical trade shows and medical meetings such as NANETs, ASCO, Healing NET
Foundation, ASCO GI, The American Association of Endocrine Surgeons,
Interventional Radiology, Digestive Disease Week, and local fairs to create awareness
pertaining to NETs among population.
In addition, in January 2018, Midatech Pharma
PLC received confirmation in oral formulation from Polish regulators for its
first in-human analysis of sustained release product Q-Octreotide (MTD201). The
product is aimed to be used as an alternative of the commercial leading
product, Sandostatin LAR.
Presence of key players such as Novartis AG,
Ipsen Pharma, Pfizer Inc., Sun Pharmaceutical Industries Ltd and Chiasma Inc.
is expected to fuel to the overall market growth. Involvement of major players
in new product development is considered to be the high contributing factor for
the SSAs market.
Browse full research report on Somatostatin
Analogs Market: https://www.grandviewresearch.com/industry-analysis/somatostatin-analogs-ssas-market
Further key
findings from the report suggest:
- Octreotide held the largest market share in
2018 due to its various therapeutic applications
- Pasireotide is estimated to be the fastest
growing segment over the forecast period
- Acromegaly held the largest share in 2018
owing to its increase prevalence
- North America dominated the market in 2018
owing to presence of key players such as Pfizer Inc. and Novartis AG
- Asia Pacific is estimated to be the fastest
growing segment with a CAGR of 9.0% over the forecast period
Browse request sample of this report by
Grand View Research: https://www.grandviewresearch.com/industry-analysis/somatostatin-analogs-ssas-market/request/rs1
Grand
View Research has segmented the global somatostatin analogs market based on
type, application and region:
Somatostatin
Analogs Type Form Outlook (Revenue, USD Million; 2015 - 2026)
- Octreotide
- Lanreotide
- Pasireotide
Somatostatin
Analogs Application Outlook (Revenue, USD Million; 2015 - 2026)
- Acromegaly
- Neuroendocrine
Tumors (NETs)
- Others
Somatostatin
Analogs Regional Outlook (Revenue, USD Million; 2015 - 2026)
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Asia Pacific
- Japan
- China
- India
- South Korea
- Singapore
- Australia
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- South Africa
- UAE
- Saudi Arabia
About Grand View Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment